Alnylam Pharmaceuticals Inc to Discuss Topline HELIOS-A Phase 3 Results of Vutrisiran - Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Alnylam Pharmaceuticals conference call to discuss top line HELIOS-A Phase III results. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speakers today, the company. Thank you. Please go ahead.
Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are John Maraganore, our Chief Executive Officer; Akshay Vaishnaw, President of R&D; and Yvonne Greenstreet, President and Chief Operating Officer.
Also on the line and available for Q&A are Pushkal Garg, Chief Medical Officer; Tolga Tanguler, Chief Commercial Officer; and Rena Denoncourt, Senior Director, Program Leader for vutrisiran.
For those of you participating via conference call, the slides we made available
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |